Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Aspergillosis Treatment Market
Aspergillosis Treatment Market Size
- Report ID: GMI9917
- Published Date: Jun 2024
- Report Format: PDF
Aspergillosis Treatment Market Size
Aspergillosis treatment market size was valued at around USD 3.8 billion in 2023 and is estimated to grow at 4.3% CAGR from 2024 to 2032. Aspergillosis treatment, where aspergillosis is a group of fungal infections caused by aspergillus species, commonly found indoors and outdoors. It ranges from mild to severe and predominantly affects individuals with weakened immune systems or existing lung conditions.
The rising incidence of aspergillosis is a significant driver for the market. For instance, according to the Centers for Disease Control and Prevention (CDC’s) report indicates that approximately 2.5% of adults diagnosed with asthma also suffer from allergic bronchopulmonary aspergillosis (ABPA), totaling around 4.8 million individuals globally. Among these ABPA cases, an estimated 400,000 people additionally contend with chronic pulmonary aspergillosis (CPA), in 2024.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Aspergillosis Treatment Market Size in 2023: | USD 3.8 Billion |
| Forecast Period: | 2024 - 2032 |
| Forecast Period 2024 - 2032 CAGR: | 4.3% |
| 2032 Value Projection: | USD 5.5 Billion |
| Historical Data for: | 2021 – 2023 |
| No. of Pages: | 231 |
| Tables, Charts & Figures: | 298 |
| Segments covered: | Type, Drug Class, Drug Form, Distribution Channel, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Therefore, this underscores the growing importance of addressing fungal infections, particularly in individuals with underlying respiratory conditions, which necessitates heightened awareness, research, and treatment options. Furthermore, growing awareness of fungal infections and development of new antifungal agents, are driving factors for the market growth.
Frequently Asked Questions (FAQ) :
Aspergillosis Treatment Market Scope
